An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis.

Current Medical Research and Opinion, 2016 04; 32(4): 721-729. e-pub ahead of print 2016/01/09

Apremilast was recently approved for the treatment of active psoriatic arthritis (PsA). However, no studies compare apremilast with methotrexate or biologic therapies, so its relative comparative efficacy remains unknown. This study compared the response rates and incremental costs per responder associated with methotrexate, apremilast, and biologics for the treatment of active PsA.

View abstract


Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.